白蛋白紫杉醇联合卡铂方案同步放疗治疗局部晚期食管癌  

Abumin-bound paclitaxel combined with carboplatin concurrent radiotherapy for locally advanced esophageal cancer

作　　者：王汉华[1] 杭业 王文才[1] 陈维维 陈金忠 顾明[1] WANG Han-hua;HANG Ye;WANG Wen-cai;CHEN Wei-wei;CHEN Jin-zhong;GU Ming(Radiotherapy Department,Yancheng Third People's Hospital,Yancheng,Jiangsu 224000,China)

机构地区：[1]盐城市第三人民医院放疗科,江苏盐城224000

出　　处：《中国临床研究》2022年第3期330-333,共4页Chinese Journal of Clinical Research

基　　金：盐城市医学科技发展计划(YK2017112)。

摘　　要：目的 探讨同步放化疗治疗中晚期食管癌的疗效。方法 选择2018年6月至2019年10月在盐城市第三人民医院进行诊治的食管癌患者72例,根据随机数字表法分为观察组与对照组,各36例。对照组给予调强放射治疗,观察组给予调强放射治疗联合同步化疗(白蛋白紫杉醇+卡铂),每21天为1个疗程,共治疗观察4个疗程,比较两组间患者的近期总有效率、1年生存率、毒副反应等。结果 观察组近期总有效率高于对照组(78.79%vs 55.56%,P<0.05)。观察组1年生存率高于对照组(81.82%vs 58.33%,P<0.05)。结论 调强放疗联合同步化学治疗较单纯调强放疗能更好地提高食管癌患者的完全缓解率及1年生存率。Objective To investigate the efficacy of concurrent radiotherapy and chemotherapy in the treatment of advanced esophageal cancer. Methods A total of 72 patients with esophageal cancer treated in Yancheng Third People’s Hospital from June 2018 to October 2019 were randomly divided into observation group and control group, with 36 cases in each group. The control group was treated with intensity modulated radiation therapy(IMRT), and the observation group was treated with IMRT combined with synchronous chemotherapy(albumin-bound paclitaxel+carboplatin). Both group was treated for 4 courses, and a course of treatment was 21 d. The short-term total effective rate, 1-year survival rate and toxic and side effects were compared between the two groups. Results The short-term total effective rate of observation group was higher than that of the control group(78.79% vs 55.56%, P<0.05). The 1-year survival rate of the observation group was higher than that of the control group(81.82% vs 58.33%, P<0.05). Conclusion IMRT combined with synchronous chemotherapy can improve the complete remission rate and 1-year survival rate of patients with esophageal cancer than IMRT alone.

关 键 词：同步放化疗 食管癌 白蛋白紫杉醇 卡铂 疗效 毒副反应 

分 类 号：R735.1[医药卫生—肿瘤] R45[医药卫生—临床医学]